Bellofatto, Marta http://orcid.org/0000-0003-3863-9419
Bertini, Alessandro
Tramacere, Irene
Manganelli, Fiore
Fabrizi, Gian Maria
Schenone, Angelo
Santoro, Lucio
Cavallaro, Tiziana
Grandis, Marina
Previtali, Stefano C.
Allegri, Isabella
Padua, Luca
Pazzaglia, Costanza
Calabrese, Daniela
Saveri, Paola
Quattrone, Aldo
Valentino, Paola
Tozza, Stefano
Gentile, Luca
Russo, Massimo
Mazzeo, Anna
Vita, Giuseppe
Piacentini, Sylvie
Pisciotta, Chiara
Pareyson, Davide http://orcid.org/0000-0001-6854-765X
Schirinzi, Giulia
Montesano, Maria
Nuzzo, Sara
Oggiano, Francesca
Gemelli, Chiara
Scarlato, Marina
Spina, Emanuele
Longo, Maria
,
Funding for this research was provided by:
Fondazione Telethon (GUP13006)
Article History
Received: 4 July 2022
Revised: 9 August 2022
Accepted: 30 August 2022
First Online: 16 September 2022
Change Date: 4 November 2022
Change Type: Update
Change Details: Some values in the table 1 columns were split into the next line and these mistakes have been updated
Declarations
:
: GMF acknowledges donations from Pfizer to support research activities of his Research Unit, financial support from Akcea, Kedrion, Pfizer for participation in national and international meetings and from Akcea, Alnylam and Pharnext for participation in Advisory Boards; MG acknowledges donations from Sanofi Genzyme to support research activities of her Research Unit, financial support from Alnylam and Sanofi Genzyme for participation in national and international meetings, participation in Advisory Board of Pfizer, speaker honorarium from Sanofi Genzyme; AM acknowledges financial support from Pfizer, Alnylam and Akcea for participation in national and international meetings, participation in Advisory Board of Pfizer, Alnylam and Akcea; GV acknowledges donations from Pfizer and PTC to support research activities and participation in Advisory Board of Pfizer, Alnylam, Akcea and Pharnext; DP acknowledges donations from Pfizer, LAM Therapeutics and Acceleron to support research activities of his Research Unit, financial support from Pfizer, Alnylam and Kedrion for participation in national and international meetings, participation in Advisory Board of Inflectis, Alnylam, Akcea, Arvinas, and Augustine Tx, speaker honorarium from Alnylam. MB, AB, IT, FM. AS, LS, TC, SCP, IA, LP, CP. DC, PS, AQ, PV, ST, LG, MR, AM, SP, CP report no disclosure.
: The study was approved by the Ethics Committee of the Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan (no. 52/2016 Date: April 2, 2014), and then by the Ethics Committees of all the other eight participating centres. It conforms with World Medical Association Declaration of Helsinki.